Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody
- 1 July 2001
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 28 (1) , 47-49
- https://doi.org/10.1038/sj.bmt.1703094
Abstract
Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.Keywords
This publication has 6 references indexed in Scilit:
- A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritisArthritis & Rheumatism, 2000
- Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host diseaseBlood, 2000
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987